Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123795 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
- 19
- Study locations
NCT04123795 is a Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 49 participants. The trial reports 19 study locations across 9 states.
The verdict
NCT04123795, a Phase 3 study of Moderate Chronic Plaque Psoriasis and Severe Chronic Plaque Psoriasis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Certolizumab pegol
Study Locations (19)
Florida
- Ps0007 50217 - Boca Raton
- Ps0007 50248 - Hialeah
- Ps0007 50169 - Jacksonville
- Ps0007 50268 - Miami
- Ps0007 50269 - Wellington
Other
- Ps0007 50183 - Calgary
- Ps0007 50225 - Calgary
- Ps0007 50187 - Edmonton
- Ps0007 50265 - San Juan
California
- Ps0007 50162 - Fountain Valley
- Ps0007 50161 - Los Angeles
- Ps0007 50196 - Thousand Oaks
Texas
- Ps0007 50156 - Arlington
- Ps0007 50277 - San Antonio
Arizona
- Ps0007 50175 - Phoenix
Georgia
- Ps0007 50230 - Rome
Illinois
- Ps0007 50168 - Chicago
Kansas
- Ps0007 50286 - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-01-21 |
| Est. Completion | 2034-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04123795
The ClinicalTrials.gov registry entry for NCT04123795 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Moderate Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04123795 reports 19 study locations spanning 9 distinct geographic areas - top geographies include Florida, Other, California.
Frequently Asked Questions
What is clinical trial NCT04123795 about?
NCT04123795 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis". The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
What is the current status of trial NCT04123795?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2020-01-21. Estimated completion is 2034-08-15.
What conditions does trial NCT04123795 study?
This clinical trial studies the following conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis.
What interventions are being tested in trial NCT04123795?
The interventions under investigation include: Placebo (DRUG), Certolizumab pegol (DRUG).
Who is sponsoring clinical trial NCT04123795?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04123795 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Moderate Chronic Plaque Psoriasis
All registered trials for this condition
Severe Chronic Plaque Psoriasis
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.